# C. Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-xu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,174 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 31 |
| i10-index | 100 |
| OpenAlex ID | https://openalex.org/A5112392157 |
| ORCID iD | 0000-0002-9021-6731 |
| Works | 391 |

## Researcher papers

- [Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation](https://scholariq.org/papers/comparison-of-droplet-digital-pcr-and-conventional-quantitative-pcr-for/)
- [Robotic surgical systems in maxillofacial surgery: a review](https://scholariq.org/papers/robotic-surgical-systems-in-maxillofacial-surgery-a-review/)
- [TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma](https://scholariq.org/papers/tp53-mutation-as-potential-negative-predictor-for-response-of-anti-ctla-4/)
- [Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study](https://scholariq.org/papers/genomic-alterations-and-clinical-outcomes-in-patients-with-lung-adenocarcinoma/)
- [TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib](https://scholariq.org/papers/tp53-mutations-predict-for-poor-survival-in-alk-rearrangement-lung/)
- [Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial](https://scholariq.org/papers/efficacy-and-safety-of-pyrotinib-in-advanced-lung-adenocarcinoma-with-her2/)
- [Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial](https://scholariq.org/papers/pyrotinib-in-patients-with-her2-amplified-advanced-non-small-cell-lung-cancer-a/)
- [MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS)](https://scholariq.org/papers/mir-513c-suppresses-neuroblastoma-cell-migration-invasion-and-proliferation/)
- [The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients](https://scholariq.org/papers/the-deep-learning-model-combining-ct-image-and-clinicopathological-information/)
- [Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study](https://scholariq.org/papers/disparity-in-clinical-outcomes-between-pure-and-combined-pulmonary-large-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.